Published in Rare Dis on August 12, 2016
Synergistic toxicity of polyglutamine-expanded TBP in glia and neuronal cells: therapeutic implications for SCA17. J Neurosci (2017) 0.75
Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci (2017) 0.75
MANF regulates hypothalamic control of food intake and body weight. Nat Commun (2017) 0.75
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Transcription of eukaryotic protein-coding genes. Annu Rev Genet (2000) 6.12
Biochemistry and structural biology of transcription factor IID (TFIID). Annu Rev Biochem (1996) 5.19
SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet (2001) 2.30
The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum (2005) 2.08
SCA17 homozygote showing Huntington's disease-like phenotype. Ann Neurol (2004) 1.72
A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet (1999) 1.69
RNA polymerase II transcription in murine cells lacking the TATA binding protein. Science (2002) 1.48
Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci (2007) 1.46
Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci (2009) 1.31
Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol (2010) 1.29
Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol (2003) 1.29
2.1 A resolution refined structure of a TATA box-binding protein (TBP). Nat Struct Biol (1994) 1.23
Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med (2011) 1.09
Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum (2008) 1.08
Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol (2004) 1.03
Induction profile of MANF/ARMET by cerebral ischemia and its implication for neuron protection. J Cereb Blood Flow Metab (2009) 1.02
Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. Clin Genet (2004) 1.02
Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol (2004) 1.01
Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J Biol Chem (2008) 0.98
Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron (2014) 0.95
Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther (2013) 0.94
Minimum prevalence of spinocerebellar ataxia 17 in the north east of England. J Neurol Sci (2005) 0.91
Molecular investigation of TBP allele length: a SCA17 cellular model and population study. Neurobiol Dis (2003) 0.90
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Activation of gene transcription by heat shock protein 27 may contribute to its neuronal protection. J Biol Chem (2009) 0.90
Neuroprotective effect of granulocyte-colony stimulating factor. Front Biosci (2007) 0.89
Therapeutic gene silencing strategies for polyglutamine disorders. Trends Genet (2009) 0.89
Role of the CCAAT-binding protein NFY in SCA17 pathogenesis. PLoS One (2012) 0.89
Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. Am J Med Genet (1996) 0.87
Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice. Cell Rep (2015) 0.85
Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17. Hum Mol Genet (2009) 0.85
A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. J Neurosci (2013) 0.84
Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol Ther (2014) 0.83
A Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome. Hum Mol Genet (2011) 0.82
Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways. Neuron (2016) 0.79
Spinocerebellar ataxia type 17: latest member of polyglutamine disease group highlights unanswered questions. Arch Neurol (2004) 0.76